## CodeSystem Comparison between http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp vs http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp

### Messages

Error | CodeSystem.version | Values for version differ: '0.1.0' vs '1.0.0'
Information | CodeSystem.date | Values for date differ: '2023-01-26T09:50:21+01:00' vs '2025-10-16T12:02:24+00:00'
Warning | CodeSystem.concept.where(code='5.1').display | Changed value for display: 'RT between 15 and 35 Gy to a vol exposing the heart' vs 'RT >=12 Gy to a vol exposing the testicles'
Information | CodeSystem.concept.where(code='5.1').definition | Changed value for definition: 'RT between 15 and 35 Gy to a vol exposing the heart' vs 'RT >=12 Gy to a vol exposing the testicles'
Warning | CodeSystem.concept.where(code='16.2').display | Changed value for display: 'Hydrocephalus or cerebrospinal fluid shunt (Risk factor for GHD)' vs 'Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)'
Information | CodeSystem.concept.where(code='16.2').definition | Changed value for definition: 'Hydrocephalus or cerebrospinal fluid shunt (Risk factor for GHD)' vs 'Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)'
Warning | CodeSystem.concept.where(code='21.2').display | Changed value for display: 'RT to a vol exposing the brain ANY DOSE' vs 'RT to a vol exposing the brain ANY DOSE'
Information | CodeSystem.concept.where(code='21.2').definition | Changed value for definition: 'RT to a vol exposing the brain ANY DOSE' vs 'RT to a vol exposing the brain ANY DOSE'
Warning | CodeSystem.concept.where(code='30.1').display | Changed value for display: 'RT to a vol exposing the gastro-intestinal tract' vs 'RT to a vol exposing the gastro-intestinal tract'
Information | CodeSystem.concept.where(code='30.1').definition | Changed value for definition: 'RT to a vol exposing the gastro-intestinal tract' vs 'RT to a vol exposing the gastro-intestinal tract'
Warning | CodeSystem.concept.where(code='32.5').display | Changed value for display: 'BCNU Carmustine' vs 'BCNU Carmustine'
Information | CodeSystem.concept.where(code='32.5').definition | Changed value for definition: 'BCNU Carmustine' vs 'BCNU Carmustine'
Warning | CodeSystem.concept.where(code='32.6').display | Changed value for display: 'CCNU Lomustine' vs 'CCNU Lomustine'
Information | CodeSystem.concept.where(code='32.6').definition | Changed value for definition: 'CCNU Lomustine' vs 'CCNU Lomustine'
Warning | CodeSystem.concept.where(code='38.1').display | Changed value for display: 'Any RT including TBI' vs 'Any RT including TBI (predominantly in the RT field)'
Information | CodeSystem.concept.where(code='38.1').definition | Changed value for definition: 'Any RT including TBI' vs 'Any RT including TBI (predominantly in the RT field)'

### Metadata

Name | Value | Comments
--- | --- | ---
caseSensitive | true |
compositional |  |
content | complete |
copyright |  |
date | 2023-01-26T09:50:21+01:00 | 2025-10-16T12:02:24+00:00 | Values Differ
description | Risk Factors used by the PCSP algorithm |
experimental | false |
hierarchyMeaning |  |
jurisdiction |  |
jurisdiction[0] | http://unstats.un.org/unsd/methods/m49/m49.htm#150 |
name | CsRiskFactorPcsp |
publisher | PanCareSurPass Project |
purpose |  |
status | active |
title | Risk Factors |
url | http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp |
version | 0.1.0 | 1.0.0 | Values Differ
versionNeeded |  |

### Concepts

Code | Display | Comments
--- | --- | ---
1.1 | RT to a vol exposing the thyroid gland |
1.2 | TBI |
1.3 | MIBG therapy (I-131 MIBG therapy) |
2.1 | RT >= 10 Gy to a vol exposing the breasts |
2.2 | OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age |
3.1 | RT >= 35 Gy to a vol exposing the heart |
3.2 | Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2 |
3.3 | RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2 |
4.1 | Alkylating agents |
4.2 | RT to a vol exposing the testes |
5.1 | RT between 15 and 35 Gy to a vol exposing the heart | RT >=12 Gy to a vol exposing the testicles | display changed from left to right definition changed from left to right
6.1 | RT to a vol exposing the testes or pelvis |  | Removed this concept
6.3 | Surgery to the spinal cord, sympathetic nerves or pelvis |
6.4 | Hypogonadal |
7.2 | RT to a vol exposing the ovaries |
8.1 | RT >= 30 Gy to a vol exposing the head or the brain |
8.2 | Cisplatin (with or without carboplatin > 1500 mg/m2) |
9.1 | RT to a vol exposing the pancreas |
10.2 | HSCT |
11.1 | RT to a volume exposing the hypothalamus or pituatary gland |
11.3 | Hypothalamic or pituitary tumour |
11.4 | Neurosurgery of the hypothalamus or pituitary gland |
12.1 | RT to a vol exposing the kidneys, heart and associated large vessels |
12.3 | Nephrectomy |
12.4 | Ifosfamide |
12.5 | Platinium based chemotherapy |
12.6 | Nitrosureas |
12.7 | Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously) |
13.1 | Cranial and/or spinal RT |
13.3 | Methotrexate |
13.4 | Gonadal failure |
13.5 | Growth hormone deficiency |
13.6 | Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment |
14.3 | High dose RT |
15.1 | Radiotherapy to a vol exposing the HP region >= 30 Gy |
15.2 | Surgery near or within the HP region |
15.3 | CNS tumours near or within the HP region |
16.1 | Radiotherapy to a vol exposing the HP region< 30 Gy |
16.2 | Hydrocephalus or cerebrospinal fluid shunt (Risk factor for GHD) | Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD) | display changed from left to right definition changed from left to right
17.1 | Radiotherapy to a vol exposing the HP region |
17.3 | Surgery near or within the HP region |  | Removed this concept
18.1 | Radiotherapy to a vol exposing the HP region |  | Removed this concept
18.3 | Surgery near or within the HP region |  | Removed this concept
19.1 | RT to a vol exposing the thyroid gland |  | Removed this concept
19.3 | Radioiodine therapy (I-131 ablation therapy) |
19.5 | Allogenic HSCT |
19.6 | Total thyroidectomy |
20.1 | RT to a vol exposing the head, brain or neck |
21.1 | History of a central nervous system tumor |
21.2 | RT to a vol exposing the brain ANY DOSE | RT to a vol exposing the brain ANY DOSE | display changed from left to right definition changed from left to right
21.4 | Brain surgery |
21.5 | High dose cytarabine IV (intravenous) |
21.6 | High dose MTX IV |
21.7 | Any Chemotherapy IT (intrathecal) |
22.1 | Vinca-Alkaloids |
22.2 | Cisplatin or carboplatin |
23.1 | RT to a vol exposing the lens |
24.1 | RT to a vol exposing the eye and orbit |
24.3 | Radioiodine therapy (I-131 ablation therapy) |  | Removed this concept
25.1 | RT to a vol exposing the craniofacial area, especially after high doses and at a young age |
25.3 | Surgery to the face, especially at a young age |
26.1 | Surgery of the spine |
26.2 | Surgery of the chest (Does not include CVC pose) |
26.3 | RT to a vol exposing the spine |
26.4 | Spinal or paraspinal malignancies |
27.1 | Cyclophosphamide |
27.3 | RT to a vol exposing the bladder |
27.5 | Cystectomy |
27.6 | Hysterectomy |
27.7 | Pelvic surgery |
27.8 | Spinal cord surgery |
28.1 | RT to a vol exposing the uterus only female |
29.1 | RT to a vol exposing the oral cavity or salivary glands |
29.4 | Chemotherapy |
30.1 | RT to a vol exposing the gastro-intestinal tract | RT to a vol exposing the gastro-intestinal tract | display changed from left to right definition changed from left to right
30.3 | Oesophageal surgery |
30.4 | Abdominal surgery |
30.5 | With a history of chronic GVHD |
31.1 | Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2 |
32.1 | RT to a vol exposing the lungs |
32.3 | Bleomycin |
32.4 | Busulfan |
32.5 | BCNU Carmustine | BCNU Carmustine | display changed from left to right definition changed from left to right
32.6 | CCNU Lomustine | CCNU Lomustine | display changed from left to right definition changed from left to right
32.7 | Thoracic surgery |
33.1 | Cisplatin Any dose |
33.3 | Carboplatin Any dose |
34.1 | RT to a volume exposing the liver |
34.3 | HSCT (irrespective of GVHD) |
34.5 | Mercaptopurine Thioguanine |
34.6 | Dactinomycin |
34.8 | Chronic viral hepatitis |
34.9 | Sinusoidal obstruction syndrome |
34.10 | Chronic GVHD |
34.11 | Liver surgery |
35.2 | Multiple red blood cell transfusions |
36.1 | Splenectomy |
36.2 | RT >= 10 Gy to a vol exposing the spleen |
36.4 | Autologus HSCT conditioned with TBI |
37.1 | Hereditary cancer sd |
38.1 | Any RT including TBI | Any RT including TBI (predominantly in the RT field) | display changed from left to right definition changed from left to right
39.1 | RT to a vol exposing the colon and rectum |
40.1 | RT to a vol exposing the oral cavity |
41.2 | Anthracyclines and/or Mitoxantrone |
41.3 | Epipodophyllotoxins or autologous |
41.4 | Autologous haematopoietic stem cell transplant |
42.1 | Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis) |
42.2 | RT to a vol exposing the bladder |  | Removed this concept
44.1 | RT to a vol exposing the lungs |  | Removed this concept
45.1 | RT to a vol exposing the head or brain |
46.2 | Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2 |
47.1 | RT to a vol exposing the kidney or urinary tract |
4.3 |  | Including TBI | Added this concept
13.7 |  | HSCT, especially with an history of GVHD | Added this concept
17.5 |  | hydrocephalus or cerebrospinal fluid shunt | Added this concept
33.2 |  | Ifosfamide Any dose | Added this concept
35.1 |  | HSCT (irrespective of GVHD) | Added this concept
36.3 |  | Allogenic HSCT (with or without TBI) | Added this concept
38.2 |  | HSCT Especially with a history of skin GvHD | Added this concept
46.1 |  | RT between 15 and 35 Gy to a vol exposing the heart | Added this concept